Publications
Loper Bright bringing more scrutiny, uncertainty to US agencies
Quoted, BioWorld
Chad Landmon, Hatch-Waxman & Biologics Chair, discusses how the Loper Bright ruling might impact the life sciences industry beyond HHS and the FDA.
Chad Landmon, Hatch-Waxman & Biologics Chair, discusses how the Loper Bright ruling might impact the life sciences industry beyond HHS and the FDA.